^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MUC1 expression + EGFR expression

i
Other names: MUC1, ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM, Mucin 1, cell surface associated, Cancer antigen 15-3, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
9ms
MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma. (PubMed, Ann Med)
The mRNA-seq showed that knocking down MUC1 affected the gene expression, DEGs mainly enriched in NF-κB and MAPK signalling pathway. MUC1 was highly expressed in A549/TAX cells, and MUC1-EGFR crosstalk with IL-6 may be due to the activation of NF-κB and MAPK pathways, which promote the enrichment of CSCs and lead to paclitaxel resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • MUC1 (Mucin 1) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
|
MUC1 expression • MUC1 expression + EGFR expression • IL6 expression • POU5F1 expression
|
paclitaxel
over1year
M1231 in Participants With Solid Tumors (clinicaltrials.gov)
P1, N=23, Completed, EMD Serono Research & Development Institute, Inc. | Active, not recruiting --> Completed | N=84 --> 23 | Trial completion date: Mar 2024 --> Jun 2023
Trial completion • Enrollment change • Trial completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability) • MUC1 (Mucin 1)
|
MSI-H/dMMR • EGFR expression • MUC1 expression • MUC1 expression + EGFR expression
|
M1231